Search

Scientists at Memorial Sloan Kettering Cancer Center (MSK) announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors.

… Monday, August 13, 2018 Bottom Line: Scientists at Memorial Sloan Kettering Cancer Center (MSK) announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors. The new cells combine two of the most promising types of immunotherapy into

The New York Proton Center (NYPC) celebrated its third anniversary, after opening its doors for treatment in August 2019.

… Wednesday, August 17, 2022 Today, the New York Proton Center (NYPC) celebrated its third anniversary, after opening its doors for treatment in August 2019. The New York Proton Center is one of the anchoring projects of the New York City Economic Development Corporation’s plan for creating an innovation

Using stem cells, scientists can create batches of cortical neurons to study schizophrenia and autism.

… Tuesday, January 24, 2017 Summary To study brain diseases, researchers need to produce abundant quantities of cortical neurons, which take a long time to develop naturally. A new study from MSK scientists shows how to dramatically decrease the time it takes to produce these important cells.  Highlights

A team of Memorial Sloan Kettering researchers reports that prostate cancer often takes an aggressive course in patients who have inherited mutations in the genes BRCA1 or BRCA2.

… Thursday, July 1, 2010 Summary A team of Memorial Sloan Kettering researchers reports that prostate cancer often takes an aggressive course in patients who have inherited mutations in the genes BRCA1 or BRCA2 . In some men, prostate cancer progresses slowly and may never cause serious problems. In others

A targeted drug shows promise for controlling pleural mesothelioma.

… Monday, May 16, 2022 Mesothelioma is a rare, aggressive cancer affecting the lining that surrounds organs. The most common form of the disease, pleural mesothelioma, develops in the tissue lining the lungs. The disease is very difficult to treat because it does not grow as a solid tumor and is usually

… Friday, April 17, 2026 John Maciejowski Awarded Chairman’s Prize John Maciejowski, a fifth-year graduate student in Prasad Jallepalli’s lab in the Molecular Biology Program, was awarded the Chairman’s Prize for his first-author paper Mps1 directs the assembly of Cdc20-inhibitory complexes during interphase

An international study led by MSK researchers has found that, when used to treat large B cell lymphoma, CAR T immunotherapy may work better when given earlier in the day.

… Monday, January 5, 2026 When it comes to giving immunotherapy to people with the most common form of lymphoma, the time of day may make a difference, according to new research from Memorial Sloan Kettering Cancer Center (MSK). People who receive chimeric antigen receptor (CAR) T cell therapy in the morning

Fourth-year student Jeff Smith received a Breast Cancer Research Program Predoctoral Traineeship Award from the Department of Defense Congressionally Directed Medical Research Programs.

… Monday, March 15, 2010 Fourth-year student Jeff Smith received a Breast Cancer Research Program Predoctoral Traineeship Award from the Department of Defense Congressionally Directed Medical Research Programs. This award is made based on the recipient’s talent, potential, and commitment to breast cancer

The pandemic has raised important issues for clinicians, and, after weighing the risks and benefits, the Colorectal Disease Management Team at MSK decided that all patients with locally advanced colorectal cancer will be treated with short-course radiation therapy rather than standard long-course chemoradiation therapy.

… Monday, May 11, 2020 The COVID-19 pandemic is consuming a significant amount of healthcare resources, especially in New York City, which became the global epicenter of the outbreak at the end of March 2020. Given the concerns around rapidly rising infection rates, impending staffing shortages, and the

Breakthrough findings illustrate the promise of precision oncology and signify a paradigm shift in drug development. Interim data from three trials show a 76 percent confirmed overall response rate in patients treated with the TRK inhibitor.

… Saturday, June 3, 2017 Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from three clinical trials presented